Yep...agree, Generics will have no chance to file until REDUCE-IT is approved. Some exclusivity will be given for REDUCE-IT unclear what this is. Amarin's not a NME and was never awarded NCE so the FDA leaves this up in the air again for exclusivity round two. So I do think there's an off chance Vascepa gets NCE for REDUCE-IT, because NCE has never been assigned. I think there's a good chance this goes to court,,,again.
BB